Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide plus ADT versus ADT in metastatic hormone-sensitive prostate cancer
2015-000735-32Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Apalutamide + ADT with Placebo + ADT (2 arms). Primary endpoints: Radiographic Progression-Free Survival (rPFS) and Overall Survival (OS). Started Jul 2015; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2015-000735-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000735-32.